24/7 Market News Snapshot 18 June, 2025 – Cel-Sci Corporation (NYSE:CVM)

June 18, 2025

DENVER, Colo., 18 June, 2025 (www.247marketnews.com) – (NYSE:CVM) are discussed in this article.
Cel-Sci Corporation (CVM) encountered fluctuating market activity today, opening at $2.44 before declining to $2.255, reflecting a decrease of approximately 2.80%. With a notable trading volume of 2.08 million shares, the heightened market interest may be attributed to recent developments, including the company’s focus on innovative cancer therapies. Traders are advised to monitor key support levels around $2.20 and watch for potential reversals that could influence future price trends.

In a significant advancement for oncology, Cel-Sci proudly recognizes the recent FDA approval of Merck’s KEYTRUDA® (pembrolizumab), aimed at adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). The expedited approval underlines the drug’s potential, particularly for those whose tumors express PD-L1 at a qualifying threshold. The Phase 3 KEYNOTE-689 trial has demonstrated a 30% reduction in the risk of recurrence and progression compared to standard treatments, marking a transformative moment in patient care.

However, it is important to highlight that the benefits of KEYTRUDA are not applicable to patients with low to zero PD-L1 levels, a group for whom existing therapies have shown limited efficacy. In a contrasting outcome, results from Cel-Sci’s own Phase 3 study on Multikine indicate a substantial 66% reduction in mortality risk for advanced HNSCC patients with low or undetectable PD-L1 expression, correlating to a five-year overall survival rate of 73%. This far exceeds the 45% survival rate of those receiving standard care.

As Cel-Sci prepares for a confirmatory study involving 212 patients, the company aims to leverage the body’s immune response before surgical treatment. This approach aligns with a commitment to advancing tailored therapies for oncology patients, particularly those often overlooked by current treatment protocols. The progress on KEYTRUDA further amplifies Cel-Sci’s mission to enhance survival outcomes and redefine treatment strategies in the fight against head and neck cancer.

Related news for (CVM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.